2023 World Conference on Lung Cancer (Posters)-EP11.03. What Are Favorable Clinicopathological Factors and Types of Therapy for Postoperatively Recurrent NSCLC Patients?

EP11.03. What Are Favorable Clinicopathological Factors and Types of Therapy for Postoperatively Recurrent NSCLC Patients? - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to investigate the clinicopathological factors and types of therapy that influence post-recurrence survival (PRS) in patients with non-small cell lung cancer (NSCLC). The researchers analyzed the data of 341 NSCLC patients who experienced recurrence after surgical resection between 2007 and 2021. The patients' clinicopathological factors and therapeutic regimens were examined, and their relationship with PRS was analyzed using statistical models.<br /><br />The results showed that the median age at recurrence was 71 years, with 68% of the patients being men. The most common histological types of tumors were adenocarcinomas (69%) and squamous cell carcinomas (23%). Locoregional recurrence was observed in 31% of the patients. EGFR mutations and ALK rearrangements were positive in 29% and 2% of the patients, respectively, who were all treated with tyrosine kinase inhibitors. Platinum doublet and immune checkpoint inhibitors (ICIs) were administered to 43% and 22% of the patients, respectively.<br /><br />The median observation period was 22.4 months, and the median survival time was 25.2 months. The 2- and 5-year PRS rates were 52% and 30%, respectively. The analysis identified several independent favorable factors for PRS, including age (75 years or older), disease-free interval of 24 months or more, driver gene alteration (EGFR or ALK positive), locoregional recurrence, and administration of ICIs.<br /><br />On the other hand, the era at recurrence (2015 or later) and platinum doublet administration were not found to be statistically relevant to PRS.<br /><br />In conclusion, besides clinical factors, driver gene alteration and the administration of ICIs were found to independently contribute to the post-recurrence survival of NSCLC patients. These findings provide insights into the factors that may influence the treatment outcomes and prognosis of recurrent NSCLC patients.

Asset Subtitle

Yuki Matsumura

Meta Tag

Speaker Yuki Matsumura

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

clinicopathological factors

types of therapy

post-recurrence survival

non-small cell lung cancer

recurrence

histological types

EGFR mutations

ALK rearrangements

tyrosine kinase inhibitors

platinum doublet